Patents by Inventor Fredrik Tiberg
Fredrik Tiberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200353086Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one ester of a sugar or sugar derivative; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid; with the proviso that the pre-formulation does not further comprise a liquid crystal hardener. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents.Type: ApplicationFiled: July 27, 2020Publication date: November 12, 2020Applicant: CAMURUS ABInventors: Fredrik TIBERG, Markus JOHNSSON, Justas BARAUSKAS
-
Publication number: 20200345719Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: ApplicationFiled: May 22, 2020Publication date: November 5, 2020Inventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Publication number: 20190350841Abstract: The present invention provides a formulation comprising a lipid matrix; at least one thiolated antioxidant; at least one bioactive agent; and optionally at least one chelating agent. The bioactive agent may be a gonadotrophin-releasing hormone (GnRH) agonist; a gonadotrophin-releasing hormone (GnRH) antagonist; a luthenizing hormone releasing hormone (LHRH); and/or a luthenizing hormone releasing hormone (LHRH) related peptide.Type: ApplicationFiled: November 16, 2018Publication date: November 21, 2019Applicant: CAMURUS ABInventors: Catalin NISTOR, Fredrik TIBERG, Krister THURESSON, Markus JOHNSSON
-
Publication number: 20190255068Abstract: The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-, or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynard's disease ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.Type: ApplicationFiled: September 15, 2017Publication date: August 22, 2019Applicant: CAMURUS ABInventors: Fredrik TIBERG, Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Publication number: 20190054177Abstract: A composition for the delayed delivery of a peptide active agent comprising: i) a salt of said peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion ii) a sustained-release delivery vehicle. Wherein said at last one negatively charged counter-ion is a halide ion, preferably a chloride or bromide ion.Type: ApplicationFiled: May 18, 2018Publication date: February 21, 2019Applicant: CAMURUS ABInventors: Markus JOHNSSON, Fredrik JOABSSON, Catalin NISTOR, Krister THURESSON, Fredrik TIBERG
-
Publication number: 20180311163Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: July 9, 2018Publication date: November 1, 2018Inventors: Krister Thuresson, Fredrik Tiberg, Markus Johansson, Ian Harwigsson, Fredrik Joabsson, Markus Johnsson
-
Publication number: 20180256496Abstract: The present invention relates to an injectable pre-formulation comprising a low viscosity mixture of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one oxygen containing organic solvent; d) at least one 5HT3 antagonist; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. Such compositions may additionally comprise polar solvents and/or further active agents such as opioid agonists and/or antagonists. Methods of treatment, particularly for management of nausea and vomiting such as for post-operative nausea and vomiting and/or therapy induced nausea and vomiting are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.Type: ApplicationFiled: September 16, 2016Publication date: September 13, 2018Applicants: Camurus AB, Camurus ABInventors: Fredrik Tiberg, Markus Johnsson, Justas Barauskas
-
Publication number: 20180250286Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: ApplicationFiled: January 9, 2018Publication date: September 6, 2018Inventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Publication number: 20180207089Abstract: The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.Type: ApplicationFiled: October 26, 2017Publication date: July 26, 2018Applicant: CAMURUS ABInventors: Catalin NISTOR, Markus JOHNSSON, Fredrik TIBERG
-
Patent number: 9974861Abstract: The present invention relates to formulation precursors (pre-formulations) for the in situ generation of compositions for the controlled release of the salts of peptide active agents, including somatostatin analogues. The invention also relates to pre-formulations of amphiphilic components and at least one salt of a peptide active agent (e.g., somatostatin analogue) for parenteral application.Type: GrantFiled: June 13, 2008Date of Patent: May 22, 2018Assignee: CAMURUS ABInventors: Markus Johnsson, Fredrik Joabsson, Catalin Nistor, Krister Thuresson, Fredrik Tiberg
-
Patent number: 9968680Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: November 24, 2014Date of Patent: May 15, 2018Assignee: CAMURUS ABInventors: Fredrik Joabsson, Margareta Linden, Krister Thuresson, Fredrik Tiberg
-
Patent number: 9937164Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: GrantFiled: July 26, 2013Date of Patent: April 10, 2018Assignee: Camurus ABInventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Publication number: 20180078647Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, pre-filled administration devices and kits containing the formulations.Type: ApplicationFiled: July 19, 2017Publication date: March 22, 2018Applicant: CAMURUS ABInventors: Fredrik Joabsson, Markus Johnsson, Fredrik Tiberg
-
Publication number: 20180015031Abstract: The present invention provides an injectable liquid formulation with controlled release comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.Type: ApplicationFiled: October 27, 2015Publication date: January 18, 2018Inventors: Fredrik TIBERG, Markus JOHNSSON, Ian HARWIGSSON
-
Publication number: 20180000943Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one ester of a sugar or sugar derivative; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid; with the proviso that the pre-formulation does not further comprise a liquid crystal hardener. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents.Type: ApplicationFiled: December 23, 2015Publication date: January 4, 2018Inventors: Fredrik TIBERG, Markus JOHNSSON, Justas BARAUSKAS
-
Patent number: 9820934Abstract: The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.Type: GrantFiled: August 22, 2008Date of Patent: November 21, 2017Assignee: CAMURUS ABInventors: Catalin Nistor, Markus Johnsson, Fredrik Tiberg
-
Publication number: 20170281537Abstract: The present invention provides a formulation comprising a lipid matrix; at least one thiolated antioxidant; at least one bioactive agent; and optionally at least one chelating agent. The bioactive agent may be a gonadotrophin-releasing hormone (GnRH) agonist; a gonadotrophin-releasing hormone (GnRH) antagonist; a luthenizing hormone releasing hormone (LHRH); and/or a luthenizing hormone releasing hormone (LHRH) related peptide.Type: ApplicationFiled: April 28, 2017Publication date: October 5, 2017Applicant: CAMURUS ABInventors: Catalin NISTOR, Fredrik TIBERG, Krister THURESSON, Markus JOHNSSON
-
Patent number: 9757461Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analog; Wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, pre-filled administration devices and kits containing the formulations.Type: GrantFiled: December 9, 2005Date of Patent: September 12, 2017Assignee: CAMURUS ABInventors: Fredrik Joabsson, Markus Johnsson, Fredrik Tiberg
-
Patent number: 9668967Abstract: The present invention provides a formulation comprising: i) a lipid matrix; ii) at least one thiolated antioxidant; iii) optionally at least one bioactive agent; and iv) optionally at least one chelating agent.Type: GrantFiled: August 21, 2009Date of Patent: June 6, 2017Assignee: CAMURUS ABInventors: Catalin Nistor, Fredrik Tiberg, Krister Thuresson, Markus Johnsson
-
Patent number: 9649382Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: December 23, 2013Date of Patent: May 16, 2017Assignee: CAMURUS ABInventors: Fredrik Joabsson, Margareta Linden, Krister Thuresson, Fredrik Tiberg